News & Views - Page 50 of 53 - Telix Pharmaceuticals Limited

Anthony Zinno, MBA Joins Telix Pharmaceuticals US

With more than 26 years of operations experience in the healthcare and life sciences field, Tony will be leading the sales organization as Vice President of Commercial Operations. Tony’s success has been built on developing and implementing business strategies, scaling and structuring organizations for growth, and developing unified cultures focused on common goals.

NDA Clinical Briefing Package Submitted to the US FDA

Telix Pharmaceuticals announces that it has submitted a complete clinical briefing package to the US FDA for its first product TLX591-CDx1

ZIRCON Phase 3 IND Submitted to the US FDA

Telix Pharmaceuticals Limited announces that it has submitted a Phase 3 IND application to the FDA for TLX250-CDx

TLX101 for Brain Cancer IPAX-1 Study Update

Telix Pharmaceuticals has released an update on the progress of its TLX101 product in the treatment of glioblastoma multiforme

University of Melbourne collaboration with Telix receives Cancer Australia research grant

Telix Pharmaceuticals announces University of Melbourne collaboration with Telix receives Cancer Australia research grant

Telix Pharmaceuticals and ATONCO Partner for Bladder Cancer

Telix Pharmaceuticals Limited and French company ATONCO S.A.S are pleased to announce they have entered into a Licence and Development Agreement that will enable ATONCO to investigate the use of Telix’s Molecularly Targeted Radiation (MTR) intellectual property for the treatment of non-muscle invasive bladder cancer that is resistant to standard therapies.

Webcast of CEO’s presentation to Jefferies 2019 London Healthcare Conference

Telix Pharmaceuticals Limited is pleased to announce that Group CEO, Dr. Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference.

Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited, to speak at Jefferies 2019 London Healthcare Conference

Dr. Christian Behrenbruch, CEO of Telix Pharmaceuticals Limited will speak at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which in 2018, hosted 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.

Telix Pharmaceuticals Program Update Q3 2019

Telix Pharmaceuticals Limited is pleased to release a Clinical Trial Program Update for Q3, 2019.

Telix Pharmaceuticals and AusHealth to Partner on Novel Therapeutics for Lung, Ovarian Cancer

Telix Pharmaceuticals Limited has today announced that Telix and AusHealth have entered into a collaboration and technology licensing agreement for a novel Molecularly Targeted Radiation (MTR) platform called APOMAB® intended for the treatment of ovarian and lung cancers.